基本信息
浏览量:52
职业迁徙
个人简介
My expertise and research interests are based on drug discovery and medicinal chemistry fields. Since 1995, when I constituted my own research group, my goals were focused on neurodegenerative disorders, leading numerous research projects on the medicinal chemistry and rational drug design of new drugs for Alzheimer’s (AD) and Parkinson’s (PD) diseases, multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS). The main areas of my research involve cholinesterase, protein kinase and phosphodiesterase inhibitors. More recently, I am also involved in the discovery of inhibitors of protein-protein interaction (PPIs), mitophagy modulators and anti-SARS-CoV-2 inhibitors.
Technology transfer is a constant in my professional career. Currently, I am author of more than 40 patent families where the owner is mainly CSIC and in some cases, NeuroPharma. In summer 2000, some of my academic results were worldwide licensed to NeuroPharma, being engaged with the company as external researcher. From February 2002 to 2008, I joined NeuroPharma as R&D Director where I have provided strategic, leadership management and guidance in R&D activities from the drug discovery to the final proof of concept in different animal models. In these years, two research projects based on molecules from my own CSIC previous laboratory reached clinical trials as disease modifying drugs for AD: NP-12, tideglusib, a ATP non-competitive GSK-3 inhibitor, and NP-61, a dual binding site AChEI and potent β-amyloid modulator, as disease modifying drugs for AD. The 2012 economic crisis destroyed the company, but I led the operation to rescue tideglusib. It was acquired by Autism Therapeutics, now AMO Pharma, with the goal to develop it for the treatment of rare diseases. After successful phases II in ASD, MD and CMD, clinical studies phase III for congenital myotonic dystrophy (CMD) are ongoing in Canada, USA, UK and New Zeland. Final data expected for June 2023. Furthermore, Phase II clinical trial for ALS will start in Switzerland in the second half of 2023.
Since February 2008, I resume my academic position in the CSIC, firstly in the Medicinal Chemistry Institute (IQM-CSIC) and since April 2014 in the Biological Research Center (CIB-CSIC), being the head of Translational Medicinal and Biological chemistry laboratory. In these years I lead different projects focused on the development of small molecules for the treatment of PD, ALS, MS, retinitis pigmentosa, fragile X and since March 2020 for the treatment of COVID-19.
In 2010, we licensed some of our new regenerative drugs to the Spanish biotech ARACLON with the aim to reach clinical trials for PD therapy. Funding by different public-private projects, we have performed all the tasks to fill the IMPD that is pending of AEMPS approval to start phase I studies. Furthermore, an innovative treatment for multiple sclerosis discovered in my group has been the basis of ANKAR PHARMA. I am one of the founders and scientific executive advisor of this spin-off that acquired patent rights from the CSIC to develop the compounds until clinical trials (in 2014, 2020 and the last three patents in 2022). I have been the coordinator of a solid network on biomedicine funded by Madrid Community that allowed me to develop innovative drugs for ALS. Finally, my laboratory is CIBERNED member and one of the only five chemistry sites of EU-OPENSCREEN, the European infrastructure platform for biological chemistry and drug screening.
I am mentor of 16 PhD (3 more ongoing), more than 45 Master thesis and many postdoctoral trainings and ERASMUS placements. I am also member of several editorial boards of different international journals (J Med Chem, Curr Med Chem, Mini Rev Med Chem, Recent Patents CNS) and book collections (RSC Drug Discovery Serie). Moreover, I act as reviewer in different calls and programs, being member of the Med1 panel (Pharmaceutical and Medical Sciences) of FWO (Flemish research agency) during 6 years (2014-2019), expert of the European Commission (EX2006C132745) and reviewer of ANEP, AEI, international agencies (France, Austria, Portugal, UK and Italy) and private research associations (Wellcome trust, Alzheimer Association, AFM, Weston Brain Institute, etc.). Furthermore, I have been and I am scientific advisor of different biotech companies such Noscira, ARACLON, AMO Pharma, Landsteiner GenMed,…
My professional career has been combined with seven maternity leaves (from February 1987 to March 2005).
研究兴趣
论文共 462 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Eva M. García‐Cuesta, P. Fernandéz Martinéz, Karthik Selvaraju, Adrián Miguel Gómez Pozo, Gianluca D’Agostino,Sofía Gardeta, Adriana Quijada-Freire, Patricia Blanco Gabella, Carlos P. Roca, Rodrigo Jiménez‐Saiz, Alfonso García‐Rubia, Blanca Soler-Palacios, Pilar Lucas, Rosa Ayala-Bueno, Noelia Santander Acerete, Yolanda R. Carrasco,Ana Martı́nez,Nuria E. Campillo, Lasse D. Jensen, José Miguel Rodrı́guez-Frade,César Santiago, Mario Mellado
openalex(2024)
Eva M García-Cuesta,Pablo Martínez,Karthik Selvaraju, Gabriel Ulltjärn, Adrián Miguel Gómez Pozo,Gianluca D'Agostino,Sofia Gardeta,Adriana Quijada-Freire, Patricia Blanco Gabella,Carlos Roca, Daniel Del Hoyo,Rodrigo Jiménez-Saiz,Alfonso García-Rubia,Blanca Soler Palacios,Pilar Lucas, Rosa Ayala-Bueno, Noelia Santander Acerete,Yolanda Carrasco, Carlos Oscar Sorzano,Ana Martinez,Nuria E Campillo,Lasse D Jensen,Jose Miguel Rodriguez Frade,César Santiago,Mario Mellado
eLife (2024)
Journal of Plant Physiologypp.154334, (2024)
Irene Molina-Panadero, Marcos Morales-Tenorio, Alfonso Garcia-Rubia, Tiziana Ginex, Khalil Eskandari,Ana Martinez,Carmen Gil, Younes Smani
FRONTIERS IN PHARMACOLOGY (2024)
Marcos Morales-Tenorio,Fátima Lasala, Alfonso Garcia-Rubia, Elnaz Aledavood,Michelle Heung,Catherine Olal,Beatriz Escudero-Pérez,Covadonga Alonso,Ana Martínez,César Muñoz-Fontela, Rafael Delgado,Carmen Gil
Journal of medicinal chemistryno. 18 (2024): 16381-16402
Neurotoxicity research/Neurotoxicity resarchno. 2 (2024)
Isabel Atienza-Navarro,Angel del Marco,Pilar Alves-Martinez, Maria de los Angeles Garcia-Perez, Alvaro Raya-Marin,Isabel Benavente-Fernandez,Carmen Gil,Ana Martinez,Simon Lubian-Lopez,Monica Garcia-Alloza
Translational stroke research (2024)
Mikel Etxebeste-Mitxeltorena,Enrique Niza, Cristián Martinez Fajardo,Carmen Gil,Lourdes Gómez-Gómez,Ana Martinez,Oussama Ahrazem
Natural products and bioprospectingno. 1 (2024)
BIOORGANIC CHEMISTRY (2024)
加载更多
作者统计
#Papers: 462
#Citation: 12937
H-Index: 57
G-Index: 93
Sociability: 7
Diversity: 0
Activity: 2
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn